{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:44:45Z","timestamp":1778863485751,"version":"3.51.4"},"reference-count":37,"publisher":"European Respiratory Society (ERS)","issue":"6","license":[{"start":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T00:00:00Z","timestamp":1568851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01EO1002, 01EO1502, 01ZX1302B, 01ZX1602B"],"award-info":[{"award-number":["01EO1002, 01EO1502, 01ZX1302B, 01ZX1602B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KO 3678\/5-1"],"award-info":[{"award-number":["KO 3678\/5-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2019,9,5]]},"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The role of macrolide\/\u03b2-lactam combination therapy in community-acquired pneumonia (CAP) of moderate severity is a matter of debate. Macrolides expand the coverage to atypical pathogens and attenuate pulmonary inflammation, but have been associated with cardiovascular toxicity and drug interactions. We developed a decision tree based on aetiological and clinical parameters, which are available<jats:italic>ex ante<\/jats:italic>to support a personalised decision for or against macrolides for the best clinical outcome of the individual patient.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We employed machine learning in a cross-validation scheme based on a well-balanced selection of 4898 patients after propensity score matching to data available on admission of 6440 hospitalised patients with moderate severity (non-intensive care unit patients) from the observational, prospective, multinational CAPNETZ study. We aimed to improve the primary outcome of 180-day survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found a simple decision tree of patient characteristics comprising chronic cardiovascular and chronic respiratory comorbidities as well as leukocyte counts in the respiratory secretion at enrolment. Specifically, we found that patients without cardiovascular or patients with respiratory comorbidities and high leukocyte counts in the respiratory secretion benefit from macrolide treatment. Patients identified to be treated in compliance with our treatment suggestion had a lower mortality of 27% (OR 1.83, 95% CI 1.48\u20132.27; p&lt;0.001) compared to the observed standard of care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Stratifying macrolide treatment in patients following a simple treatment rule may lead to considerably reduced mortality in CAP. A future randomised controlled trial confirming our result is necessary before implementing this rule into the clinical routine.<\/jats:p><\/jats:sec>","DOI":"10.1183\/13993003.00824-2019","type":"journal-article","created":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T18:54:10Z","timestamp":1568919250000},"page":"1900824","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning"],"prefix":"10.1183","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2051-7667","authenticated-orcid":false,"given":"Rainer","family":"K\u00f6nig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Oswald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Forstner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gernot","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Witzenrath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Welte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Kolditz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8157-2753","authenticated-orcid":false,"given":"Mathias","family":"Pletz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2019,9,19]]},"reference":[{"key":"2024102101104280000_54.6.1900824.1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/MCP.0000000000000052","article-title":"Community-acquired pneumonia","volume":"20","author":"Remington","year":"2014","journal-title":"Curr Opin Pulm Med"},{"key":"2024102101104280000_54.6.1900824.2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-004-3107-z"},{"key":"2024102101104280000_54.6.1900824.3","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.2000.15d21.x"},{"key":"2024102101104280000_54.6.1900824.4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00065212"},{"key":"2024102101104280000_54.6.1900824.5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10096-011-1272-4","article-title":"Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality","volume":"31","author":"Welte","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024102101104280000_54.6.1900824.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.09.029"},{"key":"2024102101104280000_54.6.1900824.7","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00078-09"},{"key":"2024102101104280000_54.6.1900824.8","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.11.2.189"},{"key":"2024102101104280000_54.6.1900824.9","doi-asserted-by":"publisher","DOI":"10.1086\/508873"},{"key":"2024102101104280000_54.6.1900824.10","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku033"},{"key":"2024102101104280000_54.6.1900824.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406330"},{"key":"2024102101104280000_54.6.1900824.12","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1001\/jamainternmed.2014.4887","article-title":"\u03b2-Lactam monotherapy vs \u03b2-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial","volume":"174","author":"Garin","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2024102101104280000_54.6.1900824.13","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00103-016-2318-7","article-title":"Das Kompetenzzentrum f\u00fcr ambulant erworbene Pneumonie. [CAPNETZ. The competence network for community-acquired pneumonia (CAP)]","volume":"59","author":"Suttorp","year":"2016","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung, Gesundheitsschutz"},{"key":"2024102101104280000_54.6.1900824.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2016.02.010"},{"key":"2024102101104280000_54.6.1900824.15","unstructured":"Bartlett RC . Medical Microbiology: Quality, Cost and Clinical Relevance . New York, John Wiley & Sons, 1974; pp. 24\u201331."},{"key":"2024102101104280000_54.6.1900824.16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-12-6"},{"key":"2024102101104280000_54.6.1900824.17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Soft"},{"key":"2024102101104280000_54.6.1900824.18","doi-asserted-by":"publisher","DOI":"10.1002\/pst.433"},{"key":"2024102101104280000_54.6.1900824.19","first-page":"597","article-title":"Propensity score: an alternative method of analyzing treatment effects","volume":"113","author":"Kuss","year":"2016","journal-title":"Dtsch Arztebl Int"},{"key":"2024102101104280000_54.6.1900824.20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"JR Stat Soc Series B Methodol"},{"key":"2024102101104280000_54.6.1900824.21","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201402-0385CI"},{"key":"2024102101104280000_54.6.1900824.22","doi-asserted-by":"publisher","DOI":"10.2174\/157488610789869184"},{"key":"2024102101104280000_54.6.1900824.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003833"},{"key":"2024102101104280000_54.6.1900824.24","doi-asserted-by":"publisher","DOI":"10.1177\/2049936114527744"},{"key":"2024102101104280000_54.6.1900824.25","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.chest.2018.11.006","article-title":"Effect of combined \u03b2-lactam\/macrolide therapy on mortality according to the microbial etiology and inflammatory status of patients with community-acquired pneumonia.","volume":"155","author":"Ceccato","year":"2019","journal-title":"Chest"},{"key":"2024102101104280000_54.6.1900824.26","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000295981.84633.bc"},{"key":"2024102101104280000_54.6.1900824.27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3389\/fimmu.2018.00302","article-title":"The immunomodulatory effects of macrolides \u2013 a systematic review of the underlying mechanisms","volume":"9","author":"Zimmermann","year":"2018","journal-title":"Front Immunol"},{"key":"2024102101104280000_54.6.1900824.28","doi-asserted-by":"crossref","first-page":"1753465817750524","DOI":"10.1177\/1753465817750524","article-title":"Defining the relationship between COPD and CVD: what are the implications for clinical practice?","volume":"12","author":"Morgan","year":"2018","journal-title":"Ther Adv Respir Dis"},{"key":"2024102101104280000_54.6.1900824.29","doi-asserted-by":"publisher","DOI":"10.3201\/eid2103.140927"},{"key":"2024102101104280000_54.6.1900824.30","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-9-62"},{"key":"2024102101104280000_54.6.1900824.31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.rmed.2018.03.035","article-title":"Long-term azithromycin therapy to reduce acute exacerbations in patients with severe chronic obstructive pulmonary disease","volume":"138","author":"Naderi","year":"2018","journal-title":"Respir Med"},{"key":"2024102101104280000_54.6.1900824.32","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200801-145OC"},{"key":"2024102101104280000_54.6.1900824.33","first-page":"19s","article-title":"Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation","volume":"37","author":"Efthimiadis","year":"2002","journal-title":"Eur Respir J Suppl"},{"key":"2024102101104280000_54.6.1900824.34","doi-asserted-by":"crossref","first-page":"16508","DOI":"10.1038\/s41598-018-34781-1","article-title":"Closed-type pre-treatment device for point-of-care testing of sputum","volume":"8","author":"Park","year":"2018","journal-title":"Sci Rep"},{"key":"2024102101104280000_54.6.1900824.35","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00438-18"},{"key":"2024102101104280000_54.6.1900824.36","doi-asserted-by":"crossref","first-page":"40S","DOI":"10.1016\/0002-9343(91)90401-I","article-title":"Clinical toleration and safety of azithromycin","volume":"91","author":"Hopkins","year":"1991","journal-title":"Am J Med"},{"key":"2024102101104280000_54.6.1900824.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(96)80179-2"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00824-2019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:23:52Z","timestamp":1740381832000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00824-2019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,19]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,12,12]]},"published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1183\/13993003.00824-2019"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00824-2019","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,19]]}}}